Annovis Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

This post was originally published on this site

Investors with losses are encouraged to contact the firm before October 18, 2021; click here to submit trade information

LOS ANGELES, Oct. 08, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Annovis Bio, Inc. (NYSE : ANVS) investors that acquired shares between May 21, 2021 and July 28, 2021. Investors have until October 18, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

After the market closed on July 28, 2021, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer’s and Parkinson’s Disease patients relative to a placebo. On July 29, 2021 Annovis’ stock price declined by $65.94 per share, or approximately 60.25%, on this news from $109.44 per share to close at $43.50 per share.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 18, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising